GlassScriptPhysician profile
Alan B Korbett
NPI 1316998115
$3,526.69
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $485 · 2021: $2,448.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $2,447.70 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $278.31 | 2019-2020 | |
| Allergan, INC. | $136.21 | 2019-2020 | |
| Neos Therapeutics, LP | $125.78 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $93.25 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $77.48 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $73.83 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $73.76 | 2019-2020 | |
| Tris Pharma INC | $73.70 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $70.27 | 2019 | |
| Arbor Pharmaceuticals, INC. | $38.21 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.68 | 2019 | |
| Lundbeck LLC | $12.51 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Korbett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.